Lupin divests its Japanese injectables business to Abu Dhabi company

Company is looking at enhancing efficiencies in Japanese market which is facing pricing pressure

Mumbai-headquartered Lupin on Thursday announced an agreement to sell its Japanese injectables business to neo ALA Co. Ltd, a wholly owned subsidiary of Abu Dhabi-based Neopharma group. The company said that the move will help to streamline its Japanese operations and enhance focus on branded generics business in Japan. 

The deal value was not disclosed. 

Japan contributes 14 per cent of Lupin's revenues and it ranks number five in that market. 

The company said that it has entered into a definitive agreement through its Japanese subsidiary Kyowa (Kyowa Pharmaceutical Industry Co., Ltd.) for the sale of its Japanese Injectables business